Boehringer Ingelheim’s BI 425809 Receives the US FDA’s Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia

May 25, 2021 Auto Bot Boehringer Ingelheim, Breakthrough Therapy Designation, FDA, regulatory, Schizophrenia 0

Shots:

  • The BTD is based on P-II 1346.9 clinical trial, which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia
  • Moreover, the company has initiated the P-III CONNEX program assessing the safety and efficacy of BI 425809 vs PBO for improving cognition in adults with schizophrenia over a 26wks. treatment period
  • Additionally, Boehringer Ingelheim will also use VeraSci’s VRFCAT which is an assessment that improves clinical trials by detecting functional improvements in patients’ everyday lives. BI 425809 is a novel glycine transporter-1 (GlyT1) inhibitor

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology

The post Boehringer Ingelheim’s BI 425809 Receives the US FDA’s Breakthrough Therapy Designation for Cognitive Impairment Associated with Schizophrenia first appeared on PharmaShots.